Elastography Imaging Market Analysis by Growth, Trends and Forecast (2024–2032) | UnivDatos
According to the UnivDatos Market Insights Analysis, the rising prevalence of breast cancer and chronic ailments and increasing demand for minimally invasive surgeries across the globe will drive the global scenario of the elastography imaging market. As per their “Elastography Imaging Market” report, the global market was valued at ~USD 4 billion in 2023, growing at a CAGR of about 10% during the forecast period from 2024-2032 to reach USD billion by 2032.
The advanced and continuously progressing nature of the elastography imaging market in North America is due to the recent technological enhancements in the market, strong infrastructure of the healthcare system, increasing prevalence of chronic diseases, growing awareness among the populace, favourable regulatory situation, and healthy competition in the market. All of these factors combine to make the region account for the largest market share in the global elastography imaging market. The elastography imaging market in North America is experiencing notable and progressive escalation, driven by a confluence of factors that enhance its adoption and growth:
Technological Advancements: North America is the leading region for employing the latest elastography technologies such as high-resolution ultrasound elastography and MRE. Technological enhancements including imaging as well as data processing algorithms enhance diagnosis and the speed at which they are done. Modern elastography systems utilize artificial intelligence and machine learning for automatic measurement and more clearer understanding of tissue stiffness. These advancements help improve the quality of patient care while making the processes within clinical practices more efficient.
Healthcare Infrastructure: The region has access to hi-tech healthcare and a good standard of medical practitioners that encourages the use of advanced equipment. The factual presence of such leading healthcare institutions and research centers contributes to the existence of a push factor that can be taken as an accelerated application of new technologies. Active capital expenditure for the health sector and technology upgrades assists in identifying and acquiring enhanced elastography imaging systems in hospitals and diagnostic facilities.
Rising Prevalence of Chronic Diseases: The rising prevalence of cases like liver diseases, cancers, and cardiovascular illnesses is attributed to the elevated use of non-invasive diagnostic services. Liver fibrosis is well evaluated with elastography, tumor staging, and myocardial stiffness further highlighting the importance of the modality in managing the disease. Most healthcare delivery systems have shifted their emphasis towards the early identification of diseases as well as preventing the onset of the same; elastography will fill this void of timely and accurate tests.
Patient and Heishcare Provider Awareness: Health care providers as well as patients in North America are getting more informed about the uses of elastography imaging. Informative activities as well as clinical teaching help in raising awareness and extending the application of such technologies. The shift to patient-friendly care preferences that do not cause discomfort or pose risks to patients makes elastography ideal for use.
Regulatory and Reimbursement Landscape: The increase in elastography systems use is enhanced by FDA approval in the U. S. and similar bodies in various countries around the world in clinical practice, hence enhancing the market. Since reimbursement for elastography procedures by health insurance companies is emerging, these procedures will be more availed thus encouraging its widespread in the healthcare setting.
Recent Advancements in North America
According to the American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2024, about 41,630 new cases (28,000 in men and 13,630 in women) will be diagnosed with cancer and about 29,840 people (19,120 men and 10,720 women) will die of these cancers.
According to the National Cancer Institute, in 2021, an estimated 3,972,256 women were living with female breast cancer in the United States.
In July 2024, U.S.-based GE HealthCare agreed to acquire Intelligent Ultrasound Group PLC’s clinical artificial intelligence (AI) software business. GE Healthcare plans to incorporate these solutions across the ultrasound portfolio, strengthening its capabilities with technology that helps improve workflows and enhance ease of use for the benefit of clinicians and patients.
